Structure Therapeutics, Inc. · NASDAQ:GPCR
Structure Therapeutics — Corporate Update (September 2026)
35 slides from Structure Therapeutics's corporate update, Sep 8, 2026
Slide 1: Amylin and GLP-1 Program Updates
1 Amylin and GLP - 1 Program Updates September 8, 2026
Slide 2: Forward-looking statements
2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward - looking statements, including
Slide 3: Today's Update
3 Today’s Update Raymond Stevens, Ph.D. Chief Executive Officer Opening Remarks and Overview of Structure’s Portfolio Strategy Blai Coll, M.D., Ph.D. Chief Medical Officer ACCG - 2671: Unlocking the Potential of Oral Amylin Advancing Aleniglipron: ACCESS 72w OLE Completion and Phase 3 Update Raymond
Slide 4: Less than 1% of Global Overweight and Obese Population Taking Anti-Obesity Medications
4 Less than 1% of the Global Population Living with Overweight and Obesity are Taking Anti - Obesity Medications CURRENTLY TREATED ~11 – 13 million patients globally 2 taking a branded anti - obesity medicines U.S. ~200 million overweight & obese 1 THE GAP BETWEEN ADDRESSABLE POPULATION AND TREATMEN
Slide 5: Unprecedented Oral GLP-1 Uptake Demonstrates Market Demand
5 Unprecedented Oral GLP - 1 Uptake Demonstrates Market Demand 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% Weekly Oral TRx Share US obesity GLP - 1 market 1 US Weekly TRx Share 1. IQVIA; Bernstein Research; J.P. Morgan 2. Novo estimate of ~1.2M U.S. patients on Wegovy pill, scaled up to include Foundayo base
Slide 6: Today's Focus: ACCG-2671 and Aleniglipron
6 Phase 2b 72 - week ACCESS OLE Completed Phase 1/2a SAD Completed Today’s Focus ACCG - 2671 POTENTIAL BEST IN CLASS ORAL SMALL MOLECULE GLP - 1 RECEPTOR AGONIST FIRST IN CLASS ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST x ~ 6 days half - life for potential once weekly dosing x No SAEs x Initial sig
Slide 7: ACCG-2671: Unlocking the Potential of Oral Amylin
7 ACCG - 2671: Unlocking the Potential of Oral Amylin Blai Coll
Slide 8: Amylin Receptor Biology
8 Amylin Receptor Biology 1. Walker et al. Nat Rev Endocrinol . 2025; doi:10.1038/s41574 - 025 - 01125 - 9; 2. Mathiesen et al. Eur J Endocrinol. 2022;186(6):R93 - R111; 3. Hay et al. Pharmacol Rev. 2015;67(3):564 - 600; 4. Dacquin et al. J Cell Biol. 2004;164(4):509 - 514; 5. Naot et al. Physiol Re
Slide 9: ACCG-2671 First-in-Class Small Molecule Amylin Agonist Demonstrated Encouraging Preclinical Activity
9 ACCG - 2671 First - in - Class Small Molecule Amylin Agonist Demonstrated Encouraging Preclinical Activity 1. 2026 American Diabetes Association Conference Poster Presentation #3061 - LB ORAL DACRA ACCG - 2671 • Broad specificity across human CTR, AMY1R, AMY2R, and AMY3R • High in vitro binding af
Slide 10: Phase 1/2a SAD Clinical Trial in Healthy Participants Without Obesity
10 Phase 1/2a SAD Clinical Trial in Healthy Participants Without Obesity Abbreviations: BMI=body mass index; PK=pharmacokinetic; MAD=multiple ascending dose; SAD=single ascending dose ACCG - 2671 • Evaluated the safety, tolerability, pharmacokinetics, and food - effect of single ascending doses of A
Slide 11: ACCG-2671 SAD Baseline Demographics
11 ACCG - 2671 SAD Baseline Demographics Pooled Placebo (N=8) 10 mg (N=6) 5 mg (N=5) 2 mg (N=6) 1 mg (N=6) Characteristic Mean (SD) or N (%) 8 (100) 6 (100) 5 (100) 6 (100) 6 (100) Completed treatment 7 (87.5) 6 (100) 5 (100) 6 (100) 6 (100) Completed trial 43.8 (12.7) 34.2 (5.9) 35.6 (0.6) 39.3 (10
Slide 12: Favorable PK Profile Demonstrated After Single Dose
12 Favorable PK Profile Demonstrated After Single Dose Single Dose PK Profiles ACCG - 2671 • Rapid absorption: maximum concentration reached in 1 – 1.5 hours • Exposure consistent with dose proportionality • Long terminal half - life of ~6 days supports potential once - weekly dosing
Slide 13: Safety and Tolerability Summary After Single Dose
13 Safety and Tolerability Summary After Single Dose ACCG - 2671 • No serious adverse events • No treatment e mergent a dverse e vents (TEAEs) leading to study discontinuation • No cases of drug - induced liver injury • Dose - related GI induction provides sign of target engagement Pooled Placebo (N
Slide 14: Early Changes in Body Weight Observed After Single Dose
14 ACCG - 2671 Day 17 * 0.2% - 0.9% 0.1% - 1.2% - 3.3% -3.5% -3.0% -2.5% -2.0% -1.5% -1.0% -0.5% 0.0% 0.5% Placebo (n=6) 1 mg (n=6) 2 mg (n=6) 5 mg (n=5) 10 mg (n=6) Day 24 * Change from Baseline in Body Weight, % *Day 17 and Day 24 were end of study for cohorts dosed at 1 - 5 mg and 10 mg, respecti
Slide 15: ACCG-2671 Reduction in CTX-1 Biomarker Observed with Single Dose
15 • Day 2 CTX - 1 decreased across every active dose ~60% compared with 8% increase in placebo • Day 2 increase in bone specific alkaline phosphatase up to 10.7% compared with placebo - 4.2% (data not shown) CTX - 1 Changes from Baseline to Day 2 CTX - 1 Change from Baseline in CTX - 1, % ACCG - 26
Slide 16: Phase 2a (12 Week) MAD Clinical Trial in Participants with Obesity
16 Phase 2a (12 Week) MAD Clinical Trial in Participants with Obesity Define MAD profile in participants with obesity Safety and tolerability Pharmacokinetics across multiple oral doses Effect on body weight after 12 weeks Develop dosing schedules and titration regimens 5 cohorts with d aily and wee
Slide 17: Advancing Aleniglipron: ACCESS OLE Completion and Phase 3 Update
17 Advancing Aleniglipron : ACCESS OLE Completion and Phase 3 Update Blai Coll
Slide 18: ACCESS OLE Informed Phase 3 Trial Design and Execution
18 ACCESS OLE Informed Phase 3 Trial Design and Execution ALENIGLIPRON ACCESS - 11.3% at 36 weeks 120 mg Baseline Titration Phase (every 4 weeks) Maintenance Phase (at target dose) ACCESS Primary Endpoint 30 15 5 N=45 N=65 N=64 N=56 45 mg 90 mg 60 30 15 5 120 mg 60 30 15 5 90 Pooled Placebo 75 90 60
Slide 19: ACCESS OLE Baseline Demographics
19 ACCESS OLE Baseline Demographics • BMI ranging between 33.9 – 39.0 kg/m 2 and normal systolic and diastolic blood pressure • Lower number of female participants in the 2.5 mg cross over cohort ALENIGLIPRON 2.5 mg Cross over * (N=38) Arm in the double - blind (DB) OLE treatment period Characterist
Slide 20: Dose Range Finding in Phase 2b ACCESS OLE
20 • ACCESS program finalized with dose ranging from 2.5 mg starting dose to 180 mg top dose • Up to 16.2% weight loss (40.5 lb ) with no evidence of plateau at top 180 mg dose Dose Range Finding in Phase 2b ACCESS OLE ALENIGLIPRON *Results based on MMRM estimates under Primary Efficacy Estimand acc
Slide 21: Time of Exposure at 180 mg in ACCESS OLE
21 Time of Exposure at 180 mg ~8 weeks in ACCESS OLE ACCESS OLE Arms 0 10 20 30 Overall Median T ime ( weeks) 40 120 mg 180 mg 16 8 27.7 7.9 28.0 7.3 3.7 4.4 2.5 mg Cross over * 45 180 mg 90 180 mg 120 180 mg 16.2% 14.4% 11.6% 9.0% 0% 5% 10% 15% 20% Body Weight Reduction * Cross over from placebo in
Slide 22: Aleniglipron Achieved Significant Responder Rates at Week 72
22 Aleniglipron Achieved Significant Responder Rates at Week 72 in ACCESS OLE Percentage of Participants, % ALENIGLIPRON 85.8 53.6 30.1 22.1 84.4 61.6 49.8 34.3 81.4 76.7 59.6 36.3 0% 20% 40% 60% 80% 100% >=5% >=10% >=15% >=20% Weight - Reduction Thresholds DB 45 mg DB 90 mg DB 120 mg 90 180mg 120 1
Slide 23: Significant Improvements Beyond Body Weight Reduction at Week 72
23 Aleniglipron Achieved Significant Improvements Beyond Body Weight Reduction at Week 72 in ACCESS OLE ALENIGLIPRON 45 180mg 90 180mg 120 180mg Clinically meaningful improvements in cardiometabolic risk factors * Results based on MMRM estimates under Primary Efficacy Estimand Change from Baseline *
Slide 24: Participant Journey: Tolerability Through 72 Weeks for the 120 mg Arm
24 ACCESS ( DOUBLE - BLIND ) · WEEKS 0 – 36 ACCESS OLE · WEEKS 36 – 72 5 mg 15 mg 30 mg 45 mg Dose 90 mg 120 mg ACCESS OLE Participant Journey: Tolerability Through 72 Weeks for the 120 mg Arm ALENIGLIPRON Participants 120 mg 180 mg 72 wk Vertical green line indicates 72 weeks. Protocol allow flexib
Slide 25: Participant Journey: Tolerability Through 72 Weeks for the 2.5 mg Cross Over
25 ACCESS OLE Participant Journey: Tolerability Through 72 Weeks for the 2.5 mg Cross Over * Data supports “start low go slow” strategy ACCESS (DOUBLE BLIND) · WEEKS 0 – 36 ACCESS OLE· WEEKS 36 – 72 Placebo 2.5 mg 5 mg 10 mg 20 mg 30 mg 60 mg 90 mg 120 - 180 mg Dose ALENIGLIPRON Participants * Cross
Slide 26: ACCESS OLE Tolerability Results (Weeks 36 to 72)
26 ACCESS OLE Tolerability Results (Weeks 36 to 72) Overall, low (<5%) treatment discontinuations due to Adverse Events *E - diary reporting is associated with an increase in the number of reported events. ** Cross over from placebo in the double - blind treatment period. Some GI events may be optim
Slide 27: Tolerability Improvement Supported by Start Low and Go Slow Titration
27 ACCESS OLE Tolerability Improvement Supported by Start Low (2.5 mg) and Go Slow Titration Strategy 65.1 % 31.7 % 11.1 % 50.0 % 18.4 % 2.6 % 0 20 40 60 80 Nausea Vomiting TEAE-led discontinuation 120 mg, Weeks 0 – 36 (N=63) DB Placebo → 180 mg, Weeks 36 – 72 (N=38) Percentage of Participants, % AL
Slide 28: Favorable Off-Target Safety Results in ACCESS OLE
28 Aleniglipron Continued to Demonstrate Favorable Off - Target Safety Results in ACCESS OLE • No cases of drug - induced liver injury (DILI) • No cases of ALT or AST ≥ 10x upper limit of normal (ULN) • All cases of elevated ALT and AST resolved without treatment discontinuation ALENIGLIPRON Overall
Slide 29: Global Phase 3 Clinical Trials Initiated
29 Global Phase 3 Clinical Trials Initiated Chronic Weight Management in Adults with Obesity or Overweight and a Weight - related Comorbidity Population Sample Size BMI ≥ 30 or ≥ 27 w/ ≥ 1 comorbidity HbA1c < 6.5% N=3,600 Chronic Weight Management in Adults with Obesity or Overweight and Type 2 Diab
Slide 30: Advancing Aleniglipron as a Potential Best-in-Class Oral GLP-1
30 Advancing Aleniglipron as a Potential Best - in - Class Oral GLP - 1 Phase 3 Design • Clinical trial design informed by the key success factors identified to date • Aligned Phase 3 program with FDA and EMA and clear path to registration • Evaluating ~4,700 participants in registrational Phase 3 c
Slide 31: Building a Leading Oral Small Molecule Obesity Portfolio for Broad Access
31 Building a Leading Oral Small Molecule Obesity Portfolio for Broad Access Raymond Stevens
Slide 32: 2026: A Transformational Year for Structure Therapeutics
32 Phase 3 Phase 2 Phase 1 IND - enabling/ DC Lead Optimization Discovery Study / Focus Molecule(s) Program Aleniglipron (GSBR - 1290) Selective GLP - 1 Receptor Agonist Backbone ACCESS OLE ACCESS II Diabetes/Obesity Body Composition SWITCH ACCG - 2671 (DACRA) Amylin Amylin Receptor Agonists Backbon
Slide 33: Anticipated Milestones and Catalysts
33 1. Cash includes cash, cash equivalents and short - term investments as of June 30, 2026 2028 2027 2029 x Phase 3 Start x ACCESS OLE Data □ Body Comp Data □ T2DM/Obesity Data □ SWITCH Data x Phase 1/2a SAD Data □ Phase 2a MAD (12 wk ) Data □ Phase 2b (36wk) Data □ Phase 1 SAD Start □ Combo Trial
Slide 34: Structure Therapeutics: Redefining Chronic Weight Management
34 Structure Therapeutics: Redefining Chronic Weight Management Our Mission: Making Medicines More Accessible to All. Focused pipeline. Broad patient impact. Our programs are advancing across distinct patient needs – supporting a long - term vision for chronic weight management . MULTIPLE ORAL PRODU
Slide 35: Q&A
35 Q&A
Structure Therapeutics — Corporate Update (September 2026) on 6ix